GO
Loading...

Biogen Idec Inc

More

  • Early Glance: Biotechnology companies Tuesday, 8 Apr 2014 | 10:43 AM ET

    Amgen Inc. rose$. 10 or. 1 percent, to $118.92. Biogen Idec fell $4.31 or 1.5 percent, to $289.88. Celgene Corp. fell $1.32 or. 9 percent, to $137.84.

  • *Eli Lilly ordered to pay $3 bln in damages in Actos case. *Alcoa earnings due after the close.

  • There’s still value in biotech stocks: Citi pro Monday, 7 Apr 2014 | 6:23 PM ET

    Despite the recent meltdown in biotech, there are still areas of opportunity within the sector, Citi's Yaron Werber says.

  • Final Glance: Biotechnology companies Monday, 7 Apr 2014 | 6:01 PM ET

    Amgen Inc. fell$. 29 or. 2 percent, to $118.82. Biogen Idec rose $5.92 or 2.1 percent, to $294.19. Celgene Corp. rose $1.78 or 1.3 percent, to $139.16.

  • Midday Glance: Biotechnology companies Monday, 7 Apr 2014 | 1:49 PM ET

    Amgen Inc. fell$. 47 or. 4 percent, to $118.64. Biogen Idec rose $4.41 or 1.5 percent, to $292.68. Celgene Corp. rose$. 89 or. 6 percent, to $138.27.

  • *E* Trade and Netflix weigh on S&P 500 and Nasdaq. NEW YORK, April 4- Momentum shares like Netflix and TripAdvisor sold off sharply for a second straight day on Friday, giving the Nasdaq its worst day since February and leaving investors anxious about how much further they may fall.

  • *E* Trade and Netflix weigh on S&P 500 and Nasdaq. NEW YORK, April 4- U.S. stocks fell sharply on Friday as momentum shares like Netflix and TripAdvisor sold off for a second straight session, putting the Nasdaq on track for its second-worst day of the year.

  • *E* Trade and Netflix weigh on S&P 500 and Nasdaq. NEW YORK, April 4- The Nasdaq tumbled more than 2 percent on Friday as momentum stocks like Netflix and TripAdvisor sold off for a second straight session.

  • *E* Trade and Netflix weigh on the S&P 500 and the Nasdaq. NEW YORK, April 4- The Nasdaq tumbled more than 2 percent on Friday, led by another selloff in momentum stocks like Netflix and TripAdvisor, as investors ignored relatively strong March jobs data. Biogen Idec Inc fell 3.6 percent to $291.

  • *Mylan up on report of Meda AB buy. *Boeing considers Mercury Systems acquisition. Biogen Idec Inc fell 4.3 percent to $288.98.

  • Hot HFT debate may claim Virtu's IPO as victim Wednesday, 2 Apr 2014 | 9:46 AM ET
    Traders on the floor of the New York Stock Exchange.

    The knock-on effects from the debate over 'rigged' markets may push high-speed trading firm Virtu to postpone its IPO.

  • 3 stocks set to break out in Q2: Paul Hickey Tuesday, 1 Apr 2014 | 6:16 PM ET

    These three stocks have pulled back to crucial support levels, Bespoke's Paul Hickey says.

  • Once powerful, 3 themes losing market muscle? Monday, 31 Mar 2014 | 6:44 PM ET

    Price action has led Jim Cramer to question whether 3 powerful themes have started to sputter out.

  • *S&P 500 rises in Q1 for its fifth straight quarterly gain. NEW YORK, March 31- U.S. stocks rose on Monday, with the S&P 500 ending both March and the first quarter of 2014 with moderate gains, after Federal Reserve Chair Janet Yellen relieved concerns about a rate hike coming earlier than expected.

  • Stocks wrapped up the session on a high note, with the Dow logging triple-digit gains, after Federal Reserve Chair Janet Yellen said there's still room for the central bank to help the economy. But major index ended relatively flat for the first quarter.

  • *S&P on track for fifth straight quarterly advance. NEW YORK, March 31- U.S. stocks rose on Monday, with the S&P 500 on track to end the first quarter of 2014 with slight gains, after Federal Reserve Chair Janet Yellen calmed concerns about a rate hike coming earlier than expected. Micron Tech climbed 7.2 percent to $23.48 while Oracle Corp added 3.6 percent to $40.98.

  • Midday Movers: Amgen, Biogen, Priceline & More Monday, 31 Mar 2014 | 12:18 PM ET

    Take a look at some of Monday's midday movers:

  • March 28- Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday. It affects about 4,000 people in the United States and 25,000 worldwide.

  • *Wall Street pares gains after late biotech selloff. NEW YORK, March 28- Global equity markets ended higher on Friday but U.S. stocks sharply pared gains after a late selloff in biotechnology shares, while euro zone government bond yields fell on renewed bets the European Central Bank will ease policy next week.

  • *Momentum stocks still in focus; Netflix falls. NEW YORK, March 28- U.S. stocks ended up on Friday but off their session highs as a late afternoon selloff in the biotechnology sector weighed on the overall market. The Nasdaq Composite Index fell nearly 3 percent for the week, marking its worst week since October 2012.

Most Popular Video

Thursday, 17 Apr 2014 | 12:58 PM ET

The FMHR traders reveal their final trades.

Friday, 18 Apr 2014 | 11:00 AM ET

Are economic growth expectations too high? CNBC's Jeff Cox explains.

Friday, 18 Apr 2014 | 12:00 PM ET

CNBC's Stephanie Landsman discusses how the luxury rental boom isn't confined to New York City and its boroughs, but that developers are seeing new opportunities in New Jersey.